scholarly journals A GC polymorphism associated with serum 25-hydroxyvitamin D level is a risk factor for hip fracture in Japanese patients with rheumatoid arthritis: 10-year follow-up of the Institute of Rheumatology, Rheumatoid Arthritis cohort study

2014 ◽  
Vol 16 (2) ◽  
pp. R75 ◽  
Author(s):  
Shinji Yoshida ◽  
Katsunori Ikari ◽  
Takefumi Furuya ◽  
Yoshiaki Toyama ◽  
Atsuo Taniguchi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factor ◽  
Cohort Study ◽  
Hip Fracture ◽  
Japanese Patients ◽  
Hydroxyvitamin D ◽  
Rheumatoid Arthritis Cohort ◽  
25 Hydroxyvitamin D

scholarly journals Association of Serum 25-Hydroxyvitamin D Deficiency with Risk of Incidence of Disability in Basic Activities of Daily Living in Adults >50 Years of Age

2020 ◽  
Vol 150 (11) ◽  
pp. 2977-2984
Author(s):  
Mariane M Luiz ◽  
Roberta Máximo ◽  
Dayane C Oliveira ◽  
Paula C Ramírez ◽  
Aline F de Souza ◽  
...  
Keyword(s):  
Vitamin D ◽  
Risk Factor ◽  
Activities Of Daily Living ◽  
Vitamin D Deficiency ◽  
Daily Living ◽  
Clinical Characteristics ◽  
Hydroxyvitamin D ◽  
Increased Risk ◽  
25 Hydroxyvitamin D

ABSTRACT Background Vitamin D deficiency compromises muscle function and is related to the etiology of several clinical conditions that can contribute to the development of disability. However, there are few epidemiological studies investigating the association between vitamin D deficiency and the incidence of disability. Objectives We aimed to assess whether vitamin D deficiency is associated with the incidence of disability in basic activities of daily living (BADL) and to verify whether there are sex differences in this association. Methods A 4-y follow-up study was conducted involving individuals aged 50 y or older who participated in ELSA (English Longitudinal Study of Ageing). The sample consisted of 4814 participants free of disability at baseline according to the modified Katz Index. Vitamin D was assessed by serum 25-hydroxyvitamin D [25(OH)D] concentrations and the participants were classified as sufficient (>50 nmol/L), insufficient (>30 to ≤50 nmol/L), or deficient (≤30 nmol/L). Sociodemographic, behavioral, and clinical characteristics were also investigated. BADL were re-evaluated after 2 and 4 y of follow-up. The report of any difficulty to perform ≥1 BADL was considered as an incident case of disability. Poisson models stratified by sex and controlled for sociodemographic, behavioral, and clinical characteristics were carried out. Results After 4-y follow-up, deficient serum 25(OH)D was a risk factor for the incidence of BADL disability in both women (IRR: 1.53; 95% CI: 1.16, 2.03) and men (IRR: 1.44; 95% CI: 1.02, 2.02). However, insufficient serum 25(OH)D was not a risk factor for the incidence of BADL disability in either men or women. Conclusions Independently of sex, deficient serum 25(OH)D concentrations were associated with increased risk of incidence of BADL disability in adults >50 y old and should be an additional target of clinical strategies to prevent disability in these populations.

scholarly journals Serum 25-Hydroxyvitamin D3 Levels Are Associated With Breslow Thickness at Presentation and Survival From Melanoma

2009 ◽  
Vol 27 (32) ◽  
pp. 5439-5444 ◽  
Author(s):  
Julia A. Newton-Bishop ◽  
Samantha Beswick ◽  
Juliette Randerson-Moor ◽  
Yu-Mei Chang ◽  
Paul Affleck ◽  
...  
Keyword(s):  
Vitamin D ◽  
Cohort Study ◽  
Retrospective Study ◽  
Serum Levels ◽  
Breslow Thickness ◽  
Hydroxyvitamin D ◽  
Vitamin D Levels ◽  
25 Hydroxyvitamin D ◽  
Vitamin D Supplements

Purpose A cohort study was carried out to test the hypothesis that higher vitamin D levels reduce the risk of relapse from melanoma. Methods A pilot retrospective study of 271 patients with melanoma suggested that vitamin D may protect against recurrence of melanoma. We tested these findings in a survival analysis in a cohort of 872 patients recruited to the Leeds Melanoma Cohort (median follow-up, 4.7 years). Results In the retrospective study, self-reports of taking vitamin D supplements were nonsignificantly correlated with a reduced risk of melanoma relapse (odds ratio = 0.6; 95% CI, 0.4 to 1.1; P = .09). Nonrelapsers had higher mean 25-hydroxyvitamin D3 levels than relapsers (49 v 46 nmol/L; P = .3; not statistically significant). In the cohort (prospective) study, higher 25-hydroxyvitamin D3 levels were associated with lower Breslow thickness at diagnosis (P = .002) and were independently protective of relapse and death: the hazard ratio for relapse-free survival (RFS) was 0.79 (95% CI, 0.64 to 0.96; P = .01) for a 20 nmol/L increase in serum level. There was evidence of interaction between the vitamin D receptor (VDR) BsmI genotype and serum 25-hydroxyvitamin D3 levels on RFS. Conclusion Results from the retrospective study were consistent with a role for vitamin D in melanoma outcome. The cohort study tests this hypothesis, providing evidence that higher 25-hydroxyvitamin D3 levels, at diagnosis, are associated with both thinner tumors and better survival from melanoma, independent of Breslow thickness. Patients with melanoma, and those at high risk of melanoma, should seek to ensure vitamin D sufficiency. Additional studies are needed to establish optimal serum levels for patients with melanoma.

Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study

2016 ◽  
Vol 43 (8) ◽  
pp. 1475-1479 ◽  
Author(s):  
Yosuke Hattori ◽  
Toshihisa Kojima ◽  
Atsushi Kaneko ◽  
Daihei Kida ◽  
Yuji Hirano ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Risk Factor ◽  
Cohort Study ◽  
Retention Rate ◽  
Significant Risk ◽  
Japanese Patients ◽  
Observational Cohort Study ◽  
Efficacy And Safety ◽  
Observational Cohort

Objective.To evaluate the rates of retention and discontinuation of adalimumab (ADA) due to efficacy and safety in Japanese patients with rheumatoid arthritis (RA).Methods.All patients with RA (n = 476) who were treated with ADA in the Tsurumai Biologics Communication Registry were enrolled.Results.The retention rate of ADA was 46% at 5 years. When focusing on insufficient efficacy, previous biologics use and high baseline disease activity were significant risk factors for up to 1 year. Methotrexate (MTX) use was a significantly low risk factor after 1 year of treatment.Conclusion.Concomitant MTX contributes to the longterm efficacy of ADA therapy.

scholarly journals 25-Hydroxyvitamin D deficiency is a risk factor for atherosclerotic cardiovascular disease: a prospective study

2021 ◽  
Author(s):  
Shan Su ◽  
Liting Wang ◽  
Xulei Tang ◽  
Nan Zhao ◽  
Conghui Guan ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Vitamin D ◽  
Risk Factor ◽  
Glucose Metabolism ◽  
Vitamin D Deficiency ◽  
Atherosclerotic Cardiovascular Disease ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Ascvd Risk

Abstract Background Vitamin D, a fat-soluble vitamin, play a protective role in the cardiovascular system. Increasing evidence has suggested that the vitamin D deficiency is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD). The aim of the present study was to investigate the correlation between serum 25-hydroxyvitamin D[25(OH)D] and the risk of ASCVD in Chinese, especially in people with type 2 diabetes mellitus(T2DM). Methods Based on the "REACTION" study conducted in 2011, 9014 residents aged 40 to 75 in Lanzhou, Gansu province were followed up from 2014 to 2016. A total of 7061 subjects with complete data from the two surveys in present study were analyzed. Baseline population was classified into four groups based on 25(OH)D quartiles, comparing the different 25(OH)D groups of ASCVD incidence after follow-up, multivariate Cox proportional hazards regression modelling was used to estimate associations between 25(OH)D levels and the risk of ASCVD and to further analyze the relationship between ASCVD risk and 25(OH)D levels in different glucose metabolism status. Results Among 7,061 subjects aged 40 to 75 years, the median serum 25(OH)D level was 15.91ng/ml, and the prevalence of vitamin D deficiency was 75.1%, merely 2.0% of those with vitamin D sufficiency. During the follow-up period of 3.3 years, 216 cases of ASCVD events were recorded. The cumulative incidence of ASCVD from lowest of 25(OH)D levels to the highest were 4.1%, 3.0%, 3.1% and 2.0%, respectively. Cox regression analysis indicated that the individuals in quartile 1 but not quartile 2 or 3 of 25(OH)D level had significantly higher rate of ASCVD than that in highest quartile, additionally, 10 ng/ml per increase in serum 25(OH)D at baseline, the ASCVD risk was reduced by 24%[hazard ratio(HR):0.761, 95% confident interval(CI):0.590- 0.980, P <0.05]. When the effects of 25(OH)D on ASCVD risk was assessed in different glucose metabolism status, the results showed that the low 25(OH)D plus T2DM was associated with high risk of ASCVD after adjustment of confounding risk factors (HR: 2.284, 95% CI: 1.242-4.202, P <0.05).The risk of ASCVD decreased by 35% as serum 25(OH)D increased by 10 ng/ml, which remained significant after stepwise adjustments ( P <0.05). Conclusions Serum 25(OH)D is independently and inversely associated with the risk of ASCVD in Chinese.Increasing vitamin D levels can effectively reduce the risk of ASCVD incidence, especially in T2DM populations.

scholarly journals Serum 25-hydroxyvitamin D level in relation to weight change and the risk of weight gain in adults of normal weight at baseline: the Norwegian HUNT cohort study

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e039192
Author(s):  
Adaline Heitz ◽  
Xiao-Mei Mai ◽  
Yue Chen ◽  
Yi-Qian Sun
Keyword(s):  
Cohort Study ◽  
Weight Gain ◽  
Weight Change ◽  
Relative Weight ◽  
Normal Weight ◽  
Secondary Outcome ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Reduced Risk

ObjectiveWe sought to investigate the relationship of serum 25-hydroxyvitamin D (25(OH)D) level with weight change and the risk of weight gain in an adult population who had normal weight at baseline and were followed up for 11 years.DesignA population-based prospective cohort study.SettingNord-Trøndelag, Norway.ParticipantsThe study included 1501 adults who participated in the second and third surveys of the Nord-Trøndelag Health Study (HUNT2 (1995–1997) and HUNT3 (2006–2008)) and had a normal body mass index ≥18.5 and <25.0 kg/m2 at baseline.Primary and secondary outcome measuresRelative weight change (%) was calculated as ((HUNT3 weight−HUNT2 weight)/HUNT2 weight×100). Relative annual weight change (%) was calculated as (relative weight change/follow-up years×100). Clinical weight gain was defined as relative weight change ≥5% over the 11 years, while annual weight gain was defined as relative annual weight change >1.25%.MethodsMultiple regression models were used to estimate adjusted coefficients for the relative annual weight change and risk ratios (RRs) for the risk of clinical weight gain and of annual weight gain.ResultsEach 25 nmol/L increase in season-standardised serum 25(OH)D level at baseline was associated with a reduction of 0.05% (95% CI −0.11 to 0.01) for relative annual weight change, a 10% (RR 0.90, 95% CI 0.82 to 0.97) reduced risk of clinical weight gain, and a 19% (RR 0.81, 95% CI 0.65 to 1.00) reduced risk of annual weight gain. A statistically significant trend was evident for the risk of clinical weight gain when 25(OH)D levels were treated as a categorical variable (p=0.006).ConclusionsThe findings suggested an inverse association of serum 25(OH)D level with the risk of clinical weight gain in adults who had normal weight at baseline over 11 years’ follow-up.

Sign in / Sign up

Export Citation Format

Share Document